HOLD / ACCUMULATE
12-mo target band: ₹1,700 (bear) / ₹2,215 (base) / ₹3,100 (bull) ·
Prob-wtd FV: ₹2,263 ·
Stance: Quality is not in question; price is fair. Accumulate aggressively into a ₹2,000–2,050 retest; the asymmetry improves the lower it goes.
Section 01
Executive Summary & Investment Thesis
Hindustan Unilever is the highest-quality consumer-staples franchise in India — 21.6% ROE, 25.2% ROIC, a +13.7% ROIC–WACC spread, ~94% FCF/PAT conversion and a net-cash balance sheet — and it is on sale relative to its own history for the first time in half a decade. At ₹2,218 the stock trades at ~50x core FY26 earnings (₹10,324 Cr ex the Kwality Walls demerger gain) and 33.9x EV/EBITDA, versus a 13-year median P/E of ~63x and a 5-year EV/EBITDA average of ~39x — a ~20% multiple discount on a business whose return profile has, if anything, improved. The catch is that this is a de-rating-overshoot play, not a cheap-cyclical play like the metals names: the bet is that the FY25 volume-stagnation narrative (2% UVG at the trough) was cyclical, validated by Q4 FY26's +6% underlying volume growth — a 15-quarter high. Our probability-weighted intrinsic value is ₹2,263 (+2%), so we initiate at HOLD / ACCUMULATE, conviction 3/5: the downside is well-protected (bear −23%) but the immediate upside (base ~flat) requires one more quarter of volume proof before the multiple re-rates toward its median.
Q4'26 Underlying Volume Growth
+6%
15-quarter high; vs 2% trough in Q3 FY26
Core P/E vs 13-yr Median
50x
vs ~63x median — ~20% discount
ROIC – WACC Spread
+13.7%
ROIC 25.2% on ~11.5% WACC
▲ Top value drivers
- A genuine multiple dislocation. 50x core vs a 63x 13-year median in a 25% ROIC, net-cash compounder. The trough re-rating to ~33x reported has already absorbed most of the bad news.
- Volume inflection confirmed. Q4 FY26 UVG of +6% (15-quarter high) plus a GST rate cut on ~40% of the portfolio (18%→5% on key SKUs) is the first hard evidence the rural/urban demand cycle has turned.
- Premiumisation re-armed. The ₹2,706 Cr Minimalist acquisition (Jan-26) buys the actives-led D2C skincare capability HUL could not build internally; new CEO Priya Nair ran Beauty & Wellbeing globally — the 32%-margin engine — signalling a premium-mix playbook.
▼ Top risks
- The Q4 print was partly GST-distorted. Strip the rate-cut pull-forward and organic volume is still short of the 7–9% that historically justified 60x. A <3% UVG in Q1 FY27 re-opens the bear case to ₹1,700.
- Royalty leakage to the parent. Unilever extracts ~₹2,200 Cr/yr (3.45% of sales, ~21% of core PAT), compounding at ~12% vs 6% revenue growth. Any hike toward 4% is a direct, minority-unfriendly EPS hit.
- Moat erosion in the best segments. Quick-commerce and D2C are most disruptive in Beauty & Personal Care — precisely the high-margin categories underwriting the premium multiple.
Macro frame — compute-cycle context
The broader AI/compute-capex thesis is a story with little direct read-through to a soap-and-shampoo franchise — and that is the point. In a market over-indexed to the AI build-out (compute, power, semis) and to AI-disrupted services (see our companion Infosys note), HUL is the deliberate non-correlated ballast: a rupee-domestic-consumption annuity whose earnings are indifferent to the AI-capex timeline. Its risk is the opposite of the AI names — not technological obsolescence but valuation and a slow-burn demand cycle.
Feature · Peak → Trough → Now
The Sentiment Arc
Valuation tells you where the multiple is; the sentiment arc tells you why — and whether the narrative that broke the stock is reversing. HUL's arc is a textbook round-trip from "compounder-at-any-price" euphoria to "defensive value trap" capitulation, with the first green shoots of a turn now visible.
◆ Peak — Sep 2024
₹3,035
PE ~61x · ATH
"Secular compounder, forever." Bulls defended 60x+ on a three-pillar stack: a 9M-outlet distribution moat, an imminent rural recovery, and a premiumisation flywheel. Macquarie PT ₹3,000; Jefferies BUY ₹3,000.
"A FMCG compounder of this quality in a 1.4bn-person market deserves a structural 55–65x."
▼ Trough — late-24 → Q3 FY26
₹2,022
PE ~33x · 52-wk low
One ugly number broke it: 2% UVG in Q3 FY26, the weakest ex-COVID volume print in a decade. The rural recovery never arrived in the P&L; quick-commerce/D2C cracked the moat narrative in B&PC; royalty hikes and the Kwality Walls demerger added noise. Five-year holders sat on ~5% vs a doubled Nifty.
"Demand slowdown, competitive pressure, distribution stress, rising royalty — an overhang on valuations." — Emkay
● Now — Apr–Jun 2026
₹2,218
PE ~50x core · turning
Q4 FY26 (30-Apr) delivered +6% UVG / +8% revenue — the first genuine beat in many quarters — aided by GST cuts on ~40% of the portfolio. No major downgrades post-results; no aggressive upgrades either. The data was good enough to stop the de-rating, not yet to trigger the re-rating.
"Q4 volume growth at a 15-quarter high… portfolio transformation driving recovery." — BusinessToday, May-26
Why the arc matters for the call
The de-rating from 61x → 33x was arguably more accurate than the bounce back to ~50x. The market has already priced out the euphoria; what it has not yet priced in is a durable return to 6%+ volume growth. That is the entire swing factor — and it is a binary read on the Q1 FY27 print (late July), Priya Nair's first full quarter. A second consecutive ≥5% UVG re-rates toward the median; a relapse below 3% confirms the structural-stagnation bears.
Section 02
Core Business Performance & Market Position
HUL is the dominant FMCG player in India across home care, beauty & personal care and foods, reaching consumers through a ~9M-outlet direct distribution network and an increasingly material modern-trade/e-commerce/quick-commerce mix. The franchise quality shows up in returns, not recent growth: revenue compounded only ~6.3% over five years and just ~1.8% over the trailing three (FY23–FY26) as input-cost-driven price deflation and a soft rural consumer suppressed the top line. The story is a return-ratio machine waiting for the volume cycle to turn.
Five-Year Financial Trajectory
| ₹ Cr | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | 5Y CAGR |
|---|
| Revenue | 47,028 | 52,446 | 60,580 | 61,896 | 61,328 | 63,763 | 6.3% |
| EBITDA | 12,700 | 13,948 | 15,284 | 15,875 | 15,951 | 16,372 | 5.2% |
| EBITDA margin | 27.0% | 26.6% | 25.2% | 25.6% | 26.0% | 25.7% | — |
| EBIT margin | 24.7% | 24.5% | 23.3% | 23.7% | 24.0% | 23.6% | — |
| PAT (core, ex-excep.) | ~7,850 | ~8,700 | ~9,800 | ~10,000 | ~10,200 | 10,324 | 5.6% |
| FCF | 5,097 | 7,995 | 8,980 | 14,012 | 10,624 | 9,667 | 13.6% |
| FCF / core PAT | 65% | 92% | 92% | 140% | 104% | ~94% | — |
Source: Screener.in, StockAnalysis, HUL FY26 press release. FY26 reported PAT ₹15,059 Cr is inflated by a ~₹4,923 Cr Kwality Walls demerger/other-income item; core PAT ₹10,324 Cr is the right earnings base. FY24 FCF/PAT >100% reflects a one-off working-capital release.
Return Ratios — the quality anchor
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|
| ROE | 18.4% | 20.4% | 20.2% | 21.1% | 21.6% |
| ROCE | 19.8% | 21.3% | 20.4% | 21.2% | 21.3% |
| ROIC | 20.8% | 22.6% | 23.2% | 24.5% | 25.2% |
| ROIC − WACC spread | +9.3% | +11.1% | +11.7% | +13.0% | +13.7% |
WACC ~11.5% (Rf 7.0% + β 0.7 × ERP 5.5%). ROIC expanded ~440bps over five years despite a growth slowdown — capital discipline, not growth, drove value creation. Screener's narrower-capital-base ROCE reads ~28%.
The revenue growth waterfall over FY24–FY26 was dominated by negative-to-flat price/mix (commodity-deflation pass-through) and weak volume, partially offset by premium-mix and the Minimalist/GSK-legacy portfolio. The inflection in Q4 FY26 — +6% volume on +8% revenue — is the first quarter in which volume, not price, did the heavy lifting.
Section 03
Segment Analysis & Sum-of-Parts
HUL reports four segments with very different return and growth profiles. Beauty & Wellbeing is the crown jewel (32% EBIT margin); Home Care is the volume engine (lower margin, mature); Foods carries a commodity-tea/coffee drag offset by Lifestyle Nutrition (Horlicks/Boost).
| Segment (FY25 base) | Revenue ₹Cr | Rev share | EBIT margin | Applied EV/EBITDA | Segment EV ₹Cr |
|---|
| Home Care | 22,972 | 37% | 19% | 25x | 1,46,250 |
| Beauty & Wellbeing | 13,073 | 21% | 32% | 40x | 2,08,000 |
| Personal Care | 9,168 | 15% | 17.5% | 28x | 75,600 |
| Foods & Refreshment | 15,294 | 25% | 18% | 22x | 74,800 |
| Corporate / royalty drag | — | — | — | 15x | (28,500) |
| Gross EV + net cash → equity | — | — | — | — | ~4,81,665 |
Segment EBITDA estimated as segment EBIT + allocated D&A. SOTP equity ≈ ₹4.82L Cr → ~₹2,050/share vs CMP ₹2,218 (~8% downside on current-year earnings). Bull SOTP (45x B&W, 30x Personal Care) → ~₹2,400. Source: EarningsDecoded, HUL filings, author build.
The SOTP at ~₹2,050 says the stock is modestly ahead of its current-year fair value — the premium is the option value of (a) Minimalist scaling to a ₹2,500 Cr+ ARR cluster, (b) the India FMCG scarcity premium, and (c) a leadership position that cannot be replicated. The single biggest swing in the SOTP is the multiple on Beauty & Wellbeing: every 5x on that segment's EV/EBITDA moves the equity value ~₹110/share.
Section 04
Market Expectations & Reverse Valuation
At EV ≈ ₹5.16L Cr, WACC 11.5%, terminal growth 4.5% and a terminal EBIT margin of 24%, the market is pricing a terminal-year EBIT of ~₹33–35K Cr — implying a decade revenue CAGR of ~8.0–8.5%. That is reasonable for India's #1 FMCG but demands a genuine, sustained volume-led recovery: the trailing 3-year revenue CAGR was only 1.8%. The Q4 FY26 reacceleration to 8% is the first credible evidence the embedded growth is deliverable; absent it, the stock is ~25–30% over-valued (the bear case).
What the price implies vs consensus vs our base case
| Parameter | Implied at CMP | Consensus | Our base case |
|---|
| Revenue CAGR (10y) | 8.0–8.5% | 7–9% | 7.0% |
| Terminal EBIT margin | 24% | 23.5–25% | 24.5% |
| Exit EV/EBITDA (yr 10) | 29–32x | ~35x | 30x |
| WACC | 11.5% | 11–12% | 11.5% |
The market is pricing roughly our base case. We sit marginally below consensus on growth — hence HOLD, not BUY, at spot.
Peer multiples
| Company | TTM P/E | EV/EBITDA | P/B | Rev growth | EBITDA mgn | ROCE | Div yld |
|---|
| HUL | 34x (core ~50x) | 33.9x | 10.7x | +5% | 25.7% | 21.3% | 1.85% |
| Nestlé India | 64.7x | 43.9x | 43.9x | ~9% | ~23% | 54.4% | 1.0% |
| Marico | 60.2x | 51.3x | ~18x | ~11% | ~20% | 41.4% | 0.5% |
| Dabur | 44.8x | 31.4x | ~9x | ~6% | ~18% | ~24% | 1.6% |
| Colgate-Palmolive India | 37.9x | ~28x | ~25x | ~8% | ~33% | ~58% | 2.3% |
| ITC | 17.3x | 12.9x | ~5x | +10% | ~38% | 36.6% | 5.0% |
HUL trades at a striking discount to Nestlé (64.7x) and Marico (60x) on P/E — historically anomalous, as HUL commanded the premium. The cheapness vs its own history and vs staples peers is the core of the thesis. Source: Dhan, StockAnalysis, GuruFocus, mid-Jun-26.
Section 05
Scenario-Based Valuation
Three 12-month scenarios, blended across a P/E and EV/EBITDA cross-check. Probability-weighted fair value = ₹2,263 (+2%).
Bear 25%
₹1,700
−23% vs CMP
Rev CAGR FY26–284%
EBITDA margin22.5%
Exit P/E38x
WACC12.0%
DriverVolume re-stalls
Base 55%
₹2,215
~flat vs CMP
Rev CAGR FY26–287%
EBITDA margin24.5%
Exit P/E45x
WACC11.5%
DriverGradual recovery
Bull 20%
₹3,100
+40% vs CMP
Rev CAGR FY26–2811%
EBITDA margin26.0%
Exit P/E58x
WACC11.0%
DriverVolume + premium re-rate
Probability-weighted target
(0.25 × ₹1,700) + (0.55 × ₹2,215) + (0.20 × ₹3,100) = ₹2,263. The distribution is right-skewed — the bull case (premiumisation + multiple reversion to the 63x median) carries more torque than the bear case loses, but the centre of gravity sits at spot. This is the statistical signature of a HOLD with an accumulate-on-weakness overlay.
Section 06
Risk Assessment Matrix
Category / Risk
Description
Prob
Impact
Execution — Volume
Q4 FY26 +6% UVG was partly GST-pull-forward; Q1 FY27 relapse below 3% breaks the recovery narrative.
M
H
Market — Competition
D2C (Minimalist-type) + quick-commerce erode share in the high-margin B&PC categories.
H
M
Financial — Royalty
Unilever royalty at 3.45% of sales (~21% of core PAT), compounding ~12%; hike toward 4% is a direct EPS hit.
M
M
Financial — Input costs
Palm oil (~35% of Home Care basket) + crude packaging; a 25%+ palm rally compresses EBITDA 100–150bps.
M
M
Market — Valuation
~50x core leaves no margin for error; any growth disappointment compresses the multiple violently.
M
H
Execution — Integration
Minimalist (₹2,706 Cr) integration costs or growth disappointment undermines the premium-mix thesis.
L
M
Regulatory — GST/tax
GST tailwind reverses or further rationalisation favours unbranded/regional players.
L
M
Macro — Rural demand
A weak monsoon / rural-income stall delays the single biggest volume catalyst.
M
H
Governance — Parent
Unilever global restructuring / further India demergers create episodic uncertainty (can also unlock value).
L
L
Section 07
Investment Recommendation
Rating: HOLD / ACCUMULATE, conviction 3/5. 12-month base target ₹2,215 (~flat); probability-weighted FV ₹2,263 (+2%); street mean ₹2,566 (+17%). Conviction score from the quant work: 58/100 — a mildly positive but not yet compellingly asymmetric setup, because the bulk of the de-rating (63x → ~50x core) has already happened and a re-rating needs a second quarter of volume proof.
- Position sizing: a 2–4% core holding in a diversified India sleeve — held as quality ballast / low-beta anchor (β ~0.7), not as an alpha bet. Size up toward the top of the range only on a sub-₹2,050 entry.
- Entry strategy: accumulate in tranches; add aggressively into a retest of the ₹2,000–2,050 zone (the 52-week-low neighbourhood and ~SOTP fair value), where the bear case is largely in the price.
- Exit strategy: trim into ₹2,800–3,000 (bull-case / prior-ATH zone). Hard thesis-break: two consecutive quarters of UVG <3%, which would re-validate structural stagnation and warrant cutting toward bear-case ₹1,700.
Section 08
Key Catalysts & Monitoring
Late Jul 2026 · Near-term
Q1 FY27 results — Priya Nair's first full quarter and the binary read on the volume recovery. ≥5% UVG = re-rating; <3% = retest of lows. BINARY
Aug–Sep 2026 · Near-term
Kharif sowing / rural-demand data; an above-normal monsoon would confirm rural recovery as structural rather than seasonal. POSITIVE
FY27 · Near-term
Further GST rationalisation on detergents/personal care could add 1–2% volume uplift. POSITIVE
FY27 · Medium-term
Minimalist integration metrics — scaling to ₹2,500 Cr+ ARR validates the premium-mix M&A thesis; slippage undermines it. BINARY
FY27 · Medium-term
Royalty renegotiation with Unilever — any upward revision toward 4% is a direct margin headwind. NEGATIVE
FY27+ · Long-term
FII rotation back into India consumer-defensives; HUL receives outsized inflow given liquidity and index weight. POSITIVE
Section 09
Final Investment Summary
Thesis
- Best-in-class consumer compounder (25% ROIC, +13.7% spread, net cash) at ~50x core vs a 63x 13-year median — a real de-rating overshoot.
- Volume cycle is turning: Q4 FY26 +6% UVG (15-quarter high) + GST tailwind on ~40% of the portfolio.
- Premiumisation re-armed via Minimalist + a Beauty-&-Wellbeing-native CEO; non-correlated ballast to an AI-heavy book.
Key risks
- Q4 print partly GST-distorted; a <3% Q1 FY27 UVG re-opens the structural-stagnation bear case (₹1,700).
- ~₹2,200 Cr/yr royalty leakage compounding faster than revenue; hike risk toward 4%.
- ~50x leaves no margin for error; quick-commerce/D2C erosion concentrated in the best margins.
Verdict — HOLD / ACCUMULATE, conviction 3/5. 12-month base ₹2,215; prob-weighted FV ₹2,263. Own it as quality ballast; back up the truck only on a ₹2,000–2,050 retest. Horizon 12–24 months.